Frontiers in Public Health,
Journal Year:
2022,
Volume and Issue:
10
Published: Oct. 10, 2022
We
aimed
to
describe
the
characteristics
of
individuals
infected
by
BA.4
or
BA.5
in
France
comparison
BA.1,
and
analyze
factors
associated
with
hospitalization
among
cases.
A
standardized
questionnaire
was
used
collect
information
on
confirmed
probable
Omicron
Hospitalization
risk
BA.4/BA.5
cases
were
analyzed
using
Poisson
regression.
Variables
a
p-value
below
0.2
univariate
analysis
priori
confounders
included
multivariable
regression
model.
The
median
age
301
investigated
47
years
97%
symptomatic.
most
common
clinical
signs
asthenia/fatigue
(75.7%),
cough
(58.3%),
fever
headache
(52.1%)
rhinorrhea
(50.7%).
Twelve
hospitalized,
27.1%
reported
factors.
No
admissions
intensive
care
no
deaths
reported.
Vaccination
status
available
for
292
cases,
20.9%
unvaccinated,
1.4%
had
received
one
dose,
38.3%
two
doses
39.4%
three
doses.
Cases
presenting
at
least
factor
almost
seventeen
times
more
likely
be
hospitalized
than
those
(aRR
=
16.72
[95%
CI2.59-326.86]).
Despite
longer
duration
differences
symptoms
their
possible
immune
escape,
sub-lineages
globally
showed
severe
presentation.
presence
disease
significantly
increased
BA.5.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(17), P. 5572 - 5572
Published: Aug. 26, 2023
This
study
aimed
to
compare
the
clinical
picture
of
COVID-19
in
initial
and
later
period
Omicron
dominance
identify
populations
still
at
risk.
A
retrospective
comparison
data
965
patients
hospitalized
during
early
Omicron's
(EO,
January-June
2022)
with
897
from
a
(LO,
July
2022-April
2023)
SARSTer
database
was
performed.
Patients
LO,
compared
EO,
were
older,
had
better
condition
on
admission,
lower
need
for
oxygen
mechanical
ventilation,
less
frequent
lung
involvement
imaging,
showed
much
faster
improvement.
Moreover,
overall
mortality
EO
14%,
higher
than
that
LO-9%.
Despite
milder
course
disease,
exceeding
15%
similar
both
groups
among
involvement.
The
accumulation
risk
factors
such
as
an
age
60+,
comorbidities,
involvement,
saturation
<90%
resulted
constant
98%
patients,
8%
30%
rate
LO
period.
Multiple
logistic
regression
revealed
odds
death
phase.
infections
caused
by
currently
dominant
subvariants,
prophylaxis
is
necessary
people
over
60
years
age,
especially
those
case
pneumonia
respiratory
failure.
Pathogens,
Journal Year:
2024,
Volume and Issue:
13(5), P. 388 - 388
Published: May 8, 2024
The
infection
by
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
associated
not
only
with
the
development
of
disease
but
also
long-term
symptoms
or
post-acute
sequelae
SARS-CoV-2
(PASC).
Multiple
lines
evidence
support
that
some
viral
antigens
and
RNA
can
persist
for
up
to
15
months
in
multiple
organs
body,
often
after
apparent
clearance
from
upper
system,
possibly
leading
persistence
symptoms.
Activation
immune
system
observed
a
prolonged
time,
providing
indirect
elements
infection.
In
gastrointestinal
tract,
could
stimulate
shaping
local
microbiota
potential
systemic
effects.
All
these
interactions
need
be
investigated,
taking
into
account
predisposing
factors,
multiplicity
pathogenic
mechanisms,
stratifying
populations
vulnerable
individuals,
particularly
women,
children,
immunocompromised
where
may
present
additional
challenges.
Virologica Sinica,
Journal Year:
2022,
Volume and Issue:
37(6), P. 786 - 795
Published: Nov. 23, 2022
The
recently
discovered
SARS-CoV-2
variant
Omicron
(B.1.1.529)
has
rapidly
become
a
global
public
health
issue.
substantial
mutations
in
the
spike
protein
this
new
have
raised
concerns
about
its
ability
to
escape
from
pre-existing
immunity
established
by
natural
infection
or
vaccination.
In
review,
we
give
summary
of
current
knowledge
concerning
antibody
evasion
properties
and
subvariants
(BA.2,
BA.2.12.1,
BA.4/5,
BA.2.75)
therapeutic
monoclonal
antibodies
sera
vaccine
recipients
convalescent
patients.
We
also
summarize
whether
vaccine-induced
cellular
(memory
B
cell
T
response)
can
recognize
specifically.
brief,
variants
demonstrated
remarkable
evasion,
with
even
more
striking
seen
BA.4
BA.5
sub-lineages.
Luckily,
third
booster
dose
significantly
increased
neutralizing
titers,
response
remains
conserved
provides
second-line
defense
against
Omicron.
Vaccines,
Journal Year:
2022,
Volume and Issue:
10(10), P. 1699 - 1699
Published: Oct. 11, 2022
From
December
2021
to
May
2022,
the
Omicron
BA.1
and
BA.2
subvariants
successively
became
most
dominant
strains
in
many
countries
around
world.
Subsequently,
have
emerged,
has
been
classified
into
five
main
lineages,
including
BA.1,
BA.2,
BA.3,
BA.4,
BA.5,
some
sublineages
(BA.1.1,
BA.2.12.1,
BA.2.11,
BA.2.75,
BA.4.6,
BA.5.1,
BA.5.2).
The
recent
emergence
of
several
generated
new
concerns
about
further
escape
from
immunity
induced
by
prior
infection
vaccination
creation
COVID-19
waves
globally.
In
particular,
BA.5
(first
found
southern
Africa,
February
2022)
displays
a
higher
transmissibility
than
other
is
replacing
previously
circulating
countries.
Critical Care Medicine,
Journal Year:
2024,
Volume and Issue:
52(8), P. 1194 - 1205
Published: March 28, 2024
Some
studies
have
examined
survival
trends
among
critically
ill
COVID-19
patients,
but
most
were
case
reports,
small
cohorts,
and
had
relatively
short
follow-up
periods.
We
aimed
to
examine
the
trend
patients
during
first
two
a
half
years
of
pandemic
investigate
potential
predictors
across
different
variants
concern
Infection,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 3, 2024
Abstract
Purpose
The
influence
of
new
SARS-CoV-2
variants
on
the
post-COVID-19
condition
(PCC)
remains
unanswered.
Therefore,
we
examined
prevalence
and
predictors
PCC-related
symptoms
in
patients
infected
with
delta
or
omicron.
Methods
We
compared
prevalences
risk
factors
acute
three
months
after
primary
infection
(3MFU)
between
delta-
omicron-infected
from
Cross-Sectoral
Platform
German
National
Pandemic
Cohort
Network.
Health-related
quality
life
(HrQoL)
was
determined
by
EQ-5D-5L
index
score
trend
groups
were
calculated
to
describe
changes
HrQoL
different
time
points.
Results
considered
758
for
our
analysis
(delta:
n
=
341;
omicron:
417).
Compared
omicron
patients,
had
a
similar
PCC
at
3MFU
(p
0.354),
whereby
fatigue
occurred
most
frequently
(n
256,
34%).
comparable
lowest
(0.75,
95%
CI
0.73–0.78)
disease
onset.
While
(69%,
348)
never
showed
declined
HrQoL,
it
deteriorated
substantially
37
(7%)
phase
which
27
Conclusion
With
quality-controlled
data
multicenter
cohort,
that
is
an
equally
common
challenge
least
population.
Developing
over
two
thirds
did
not
experience
any
restrictions
their
due
3MFU.
Clinical
Trail
registration
cohort
registered
ClinicalTrials.gov
since
February
24,
2021
(Identifier:
NCT04768998).
Annals of Clinical Epidemiology,
Journal Year:
2023,
Volume and Issue:
5(2), P. 31 - 36
Published: Jan. 1, 2023
The
Omicron
variant
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
emerged
in
November
2021
and
spread
worldwide.
This
review
summarizes
the
reported
mortality
morbidity
rates
disease
(COVID-19)
caused
by
variants.
In
21
previous
studies,
patients
infected
with
variants
ranged
from
0.01
to
13.1%,
whereas
that
those
was
0.08%
29.1%.
proportions
intensive
care
unit
admissions
mechanical
ventilation
were
lower
for
than
Future
studies
should
clarify
mechanisms
transmissibility
severity
COVID-19